NYSE
ACH
Last Price
US $3.59
KEY FIGURES
MKT CAP
$255.8M
EPS
TTM
$-14.11
PEG
TTM
N/M
P/E
TTM
N/M
P/S
TTM
0.09x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Accendra Health, Inc. cash flow to debt ratio of -4.56% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Accendra Health, Inc.'s free cash flow has decreased 354.67% from $-66.67M last year to $-303.12M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Accendra Health, Inc.'s debt to equity ratio is -4.67, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Healthy debt to equity ratio development.
Accendra Health, Inc.'s debt to equity ratio is -4.67, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Net debt/EBITDA.
Accendra Health, Inc. has a net debt to EBITDA ratio of 8.88x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk
Financial risk - ICR.
Accendra Health, Inc.'s interest coverage ratio is 1.63, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Accendra Health, Inc.'s profit margin has decreased (1.08K%) in the last year from -3.39% to -39.84%, signaling decreasing performance
Financial risk - Short term assets vs short term liabilities.
Accendra Health, Inc.'s short-term liabilities of $947.08M exceed its short-term assets of $547.87M, signaling financial risk
Decreasing performance - ROA.
Accendra Health, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
Accendra Health, Inc.'s return on equity of 264.54%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Accendra Health, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Accendra Health, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Accendra Health, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Accendra Health, Inc. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Accendra Health, Inc.'s yearly earnings has decreased 203.47% since last year from $-362.69M to $-1.10G, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
Accendra Health, Inc.'s yearly revenue has decreased -74.19% since last year from $10.70G to $2.76G, signaling decreasing performance
Increasing performance - ROIC.
ROIC 9.77% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Decreasing performance - 3-year revenue CAGR.
Accendra Health, Inc.'s 3-year revenue CAGR of -34.78% is negative, indicating declining revenue over the past 3 years
Increasing performance - Revenue consistency.
Accendra Health, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Accendra Health, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Accendra Health, Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Accendra Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Accendra Health, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Accendra Health, Inc. has an EV/EBITDA ratio of 8.86x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Accendra Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Accendra Health, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Undervalued - P/S ratio.
Accendra Health, Inc. has a price-to-sales ratio of 0.09x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
264.54%
Return on equity
ROIC: 9.77%
Valuation History
-0.24X
Price to Earnings
EV/EBITDA: 8.9X
Cash flow
Profit margin
-20.10%
(FY vs FY)
EBITDA Y/Y
-7.44%
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $3.59
—
Default assumptions
EBITDA Multiple
Fair Value
Market $3.59
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.